|drug824||Methylprednisolone Sodium Succinate Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.06|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
This is a double-blind, randomized, placebo-controlled, phase IIb clinical trial to assess the efficacy and safety of injectable methylprednisolone sodium succinate (MP) in patients with severe acute respiratory syndrome (SARS) in COVID-19 infection. A total of 420 individuals of both sexes, aged over 18 years old, with symptoms suggestive or confirmed diagnosis of severe acute respiratory syndrome (SARS), hospitalized at the Hospital and Pronto-Socorro Delphina Rinaldi Abdel Aziz (HPSDRAA), with clinical and radiological findings suggestive of SARS-CoV2 infection, will be randomized at a 1:1 ration to receive either MPS (0.5mg/kg of weight, twice daily, for 5 days) or placebo (saline solution, twice daily, for 5 days).
Description: Mortality rate on day 28, after randomizationMeasure: Mortality rate at day 28 Time: on day 28, after randomization
Description: Number of patients with diagnosis of early onset of SARSMeasure: Proportion of patients with SARS Time: after randomization, up to 7 days.
Description: Proportion of patient that died on days 7, 14 and 28.Measure: Mortality rate on days 7, 14 and 28 Time: after randomization, up to 28 days.
Description: proportion of patients requiring orotracheal intubationMeasure: Incidence of orotracheal intubation Time: after randomization, up to 7 days.
Description: Proportion of patients with oxygenation index (PaO2 / FiO2) < 100 in 7 days.Measure: Change in oxygenation index Time: after randomization, up to 7 days.